This series of fact sheets entitled "What it Means for You" is presented to relay the results of research results to specific interests in various types of cancer. These fact sheets can be a communication aid in visiting with your physician or an aid for the physician when talking with a patient.

Please click on each title to download the pdf file. You will need Adobe reader to view the files. These fact sheets were funded by Eli Lilly and Company Foundation.

The Trastuzumab (Herceptin®) Studies: What it Means for You (76kb)
This fact sheet is of particular interest to newly diagnosed breast cancer patients who have HER2 positive tumors.

The Bevacizumab (Avastin®) Study: What it Means for You (68kb)
This fact sheet is of particular interest to patients who are newly diagnosed with a locally recurrent or metastatic breast cancer.

The Letrozole Study: What it Means for You (71kb)
Randomized trial of Letrozole in postmenopausal women after 5 years of Tamoxifen.

The Exemestane Study: What it Means for You (259kb)
This fact sheet is of particular interest to breast cancer survivors who have been on Tamoxifen.

The Sunitinib Malate (Sutent®) and Temsirolimus (Torisel®) Studies: What it Means for You (74kb)
This fact sheet is of particular interest to patients who have advanced kidney cancer [renal cell carcinoma(RCC)].

A Review of Adjuvant Treatment for Early Stage Lung Cancer: What it Means for You (77kb)
This fact sheet is of particular interest to patients who have been diagnosed with early stage, non-small cell lung cancer.